HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SAR 020106

a CHK1 inhibitor; structure in first source

Also Known As:

SAR-020106; SAR020106

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - SAR 020106: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - SAR 020106: 3

Experts

1.	Alcaraz-Sanabria, Ana: 1 article (11/2020)
2.	Burgos, Miguel: 1 article (11/2020)
3.	Corrales-Sanchez, Veronica: 1 article (11/2020)
4.	Galan-Moya, Eva M: 1 article (11/2020)
5.	Martinez-Canales, Sandra: 1 article (11/2020)
6.	Montero, Juan Carlos: 1 article (11/2020)
7.	Nieto-Jimenez, Cristina: 1 article (11/2020)
8.	Nuncia-Cantarero, Miriam: 1 article (11/2020)
9.	Ocaña, Alberto: 1 article (11/2020)
10.	Pandiella, Atanasio: 1 article (11/2020)

Related Diseases

1.	Neoplasms (Cancer) 03/15/2013 - "SAR-020106 suppressed-radiation-induced G2/M arrest and reduced clonogenic survival only in p53-deficient tumor cells. " 11/27/2020 - "Here, using a panel of basal-like cancer cell lines, we explored the synergistic interactions of CHK1 inhibitors (rabusertib and SAR020106) with approved therapies in breast cancer and evaluated their potential to overcome resistance. "
2.	Glioblastoma (Glioblastoma Multiforme) 10/21/2019 - "The Chk1 inhibitor SAR-020106 is a potent sensitizer for DNA damage-induced cell death in glioblastoma therapy strongly reducing clonogenicity of tumour cells. " 10/21/2019 - "The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment."
3.	Breast Neoplasms (Breast Cancer) 11/27/2020 - "Here, using a panel of basal-like cancer cell lines, we explored the synergistic interactions of CHK1 inhibitors (rabusertib and SAR020106) with approved therapies in breast cancer and evaluated their potential to overcome resistance. "
4.	Aneuploidy (Aneuploid) 03/15/2013 - "SAR-020106 promoted mitotic entry following irradiation in all cell lines, but p53-deficient cells were likely to undergo apoptosis or become aneuploid, while p53 wild-type cells underwent a postmitotic G1 arrest followed by subsequent normal cell cycle re-entry. "

Related Drugs and Biologics

1.	Decitabine
2.	Temozolomide (Temodar)

Related Therapies and Procedures

1.	Therapeutics